🚨 Breaking News 🚨
The FDA has officially declared tirzepatide, the active ingredient in Eli Lilly’s Zepbound and Mounjaro, no longer in shortage. This decision has major implications for compounded tirzepatide, 503A and 503B pharmacies, and the future accessibility of GLP-1s.
In this video, Christopher and Laraine Durham break down what this announcement means for patients, the timeline leading up to the decision, and how it could impact those relying on compounded options. Together, we’ll discuss:
The FDA’s 60-90 day transition period for compounded tirzepatide.
The role of 503A pharmacies moving forward.
The potential ripple effects for semaglutide (Ozempic and Wegovy).
A call for Eli Lilly to release Zepbound vials at all doses to make this life-changing medication more affordable and accessible.
What patients can do now to stay prepared, including reporting shortages directly to the FDA.
🎥 Join us as we dive into the latest updates and provide practical advice to help you navigate these changes. Don’t forget to like, subscribe, and share to stay informed about everything happening in the world of GLP-1s.
📌 Useful Links:
Report drug shortages to the FDA: [ Ссылка ]
FDA ORDER: chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/[ Ссылка ]
💬 Tell us your thoughts: How will this decision impact you? Are you worried about access to your medications? Share your story in the comments below!
#BreakingNews #GLP1 #Tirzepatide #FDA #Zepbound #Mounjaro #CompoundedMedications #ObesityTreatment #WeightLoss
